Drug intelligence / Profile preview

UE2316

Development stage: Preclinical
Lead developer: University of Edinburgh
Modality: Small Molecules
Administration: Oral, Subcutaneous, Intracerebroventricular

Overview

UE2316 is a potent and selective inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). It has been shown to improve memory in aged, cognitively impaired mice, including after intracerebroventricular administration. UE2316 is also involved in the prevention of stress-induced suppression of hippocampal synaptic potentiation. It has implications in treating cognitive impairments and may play a role in conditions like Alzheimer's disease. Additionally, UE2316 has been used in models of liver fibrosis and insulin resistance.

Targets

HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)

Beyond the preview

Go deeper on UE2316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UE2316.

Explore the full profile